Colfosceril palmitate is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. It was part of the first generation of commercially available artificial surfactants.
- Mechanism
- Curator reviewed · 3 references
Treatment with colfosceril palmitate aims to reinflate a collapsed area of the lung, improve compliance and reduce intrapulmonary shunting. The actions of colfosceril palmitate are perfomed by replacing the defficient or innefective endogenous lung surfactant and thus, reducing the tension and stabilizing the alveoli from collapsing. Colfosceril palmitate will form a very thin film that will cover the surface of the alveolar cells and therefore it will reduce surface tension.
- Primary indication
- Colfosceril palmitate is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants.Curator reviewed
- Formula / weight
- C40H80NO8P · 734.0389 g/mol (avg)
- First approval
- Canada, 2001 · United States, 2013
- Also known as
- Dipalmitoylphosphatidylcholine
- Code names
- 129Y83
Resolves to
KILNVBDSWZSGLL-KXQOOQHDSA-NSMILESCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCWhat you can answer from here — as of July 03, 2026
Which drugs share a target with Colfosceril palmitate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account